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ABSTRACT 10 
Intravesical drug administration is used to deliver cytotoxic agents through a catheter to 11 
treat bladder cancer. One major limitation of this approach is poor retention of the drug 12 
in the bladder due to periodic urine voiding. Mucoadhesive dosage forms thus offer 13 
significant potential to improve drug retention in the bladder. Here, we investigate 14 
thiolated silica nanoparticles retention on porcine bladder mucosa in vitro, quantified 15 
through Wash Out50 (WO50) values, defined as the volume of liquid necessary to 16 
remove 50% of the adhered particles from a mucosal tissue. Following irrigation with 17 
artificial urine solution, the thiolated nanoparticles demonstrate significantly greater 18 
retention (WO50 up to 36 mL) compared to non-mucoadhesive dextran (WO50 7 mL), but 19 
have weaker mucoadhesive properties than chitosan (WO50 89 mL). PEGylation of 20 
thiolated silica reduces their mucoadhesion with WO50 values of 29 and 8 mL for 21 
particles decorated with 750 and 5000 Da PEG, respectively. The retention of thiolated 22 
silica nanoparticles is dependent on their thiol group contents and physical dimensions.   23 
  24 
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1 INTRODUCTION 30 
Urinary bladder cancer and interstitial cystitis are widespread and serious urological 31 
conditions;  bladder cancer is the ninth most common cancer in the world, with 32 
approximately 430,000 new patients diagnosed with this condition in 2012 (WCRF, 33 
2015). Intravesical drug delivery administers therapeutic agents directly into the urinary 34 
bladder via a catheter (Malmstrom, 2003, Gasion and Cruz, 2006, Nirmal et al., 2012, 35 
Haupt et al., 2013).  This provides localized treatment, minimizes systemic side effects 36 
and allows direct exposure of the affected tissue to therapeutic agents. However, 37 
intravesical drug delivery also has some limitations. The normal capacity of the bladder 38 
is 400‒600 mL, but filling to 150‒300 mL causes the urge to urinate. Due to periodical 39 
voiding of urine from the bladder, instilled drug formulations can be rapidly washed out, 40 
requiring frequent repeated administration (Guhasarkar and Banerjee, 2010). 41 
Additionally, frequent use of catheters is inconvenient for the patients and may cause 42 
inflammatory reactions and infections.  43 
The residence time of a dosage form in the bladder can potentially be improved by 44 
using mucoadhesive materials, which could adhere to the epithelial mucosa and resist 45 
drug washout.  Mucoadhesive formulations for intravesical drug delivery must satisfy 46 
three main criteria: they should adhere rapidly to the bladder mucosa, should not 47 
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interfere with the normal functions of the bladder and should be retained in situ even 48 
after urination (Tyagi et al., 2006).  49 
Hydrophilic polymers are traditionally used as mucoadhesive materials in many 50 
formulations for transmucosal drug delivery (Peppas, 1996; Andrews, 2009; 51 
Khutoryanskiy, 2011) and commonly used are chitosan and carbomers (weakly cross-52 
linked poly(acrylic acid). The adhesion of these polymers to mucosal surfaces is through 53 
non-covalent interactions such as hydrogen bonding, electrostatic attraction, 54 
hydrophobic effects and diffusion and interpenetration (Khutoryanskiy, 2011). Recently, 55 
a number of chemical approaches have been reported to enhance mucoadhesive 56 
properties of polymers including the introduction of thiol groups (Bernkop-Schnürch, 57 
2004), acrylate groups (Davidovich-Pinhas, 2011), catechols (Kim, 2015) and boronates 58 
(Liu, 2015).  59 
The literature contains few reports on chemically modified and enhanced mucoadhesive 60 
materials for intravesical drug delivery. Barthelmes et al (2011, 2013) used thiolated 61 
particles based on chitosan and demonstrated that retention in rat bladder in vivo was 62 
approximately 170-fold greater than for a small-molecular weight fluorescent marker. 63 
Storha et al (2013) developed thiolated nanoparticles using thiol-ene click chemistry and 64 
studied their retention on porcine urinary bladder mucosa in vitro. Zhang et al (2014) 65 
reported the synthesis of a series of β-cyclodextrin modified mesoporous silica 66 
nanoparticles with hydroxyl, amino, and thiol groups. They demonstrated that retention 67 
of thiol-functionalized nanoparticles on the urothelium was significantly higher than the 68 
hydroxyl- and amino-functionalized materials. 69 
Previously we have reported the synthesis of thiolated silica nanoparticles using self-70 
condensation of (3-mercaptopropyl)trimethoxysilane in dimethylsulfoxide 71 
(Irmukhametova, 2011; Irmukhametova 2012; Mun, 2014a). These nanoparticles 72 
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exhibited strong adhesion to ocular tissues and withstood repetitive washes with 73 
artificial tear fluid (Irmukhametova, 2011; Mun, 2014b). Here, we evaluate the retention 74 
of thiolated and PEGylated silica nanoparticles on porcine urinary bladder in vitro and 75 
show the effects of nanoparticle size on their mucoadhesive properties. Retention of the 76 
nanoparticles depends on both their thiol content and dimensions. Further, we introduce 77 
a novel quantitative method to compare the retention efficiency of liquid formulations on 78 
mucosal tissues through the use of Wash Out50 (WO50) values, defined as the volume of 79 
a biological fluid required to wash out 50% of a mucoadhesive formulation from a 80 
substrate.  81 
 82 
2 MATERIALS AND METHODS 83 
2.1 GENERAL MATERIALS 84 
     (3-Mercaptopropyl)-trimethoxysilane (MPTS), dimethyl sulfoxide, dimethyl 85 
formamide, acetonitrile, L-cysteine hydrochloride, 5,5’-dithiobis(2-nitrobenzoic acid), 5-86 
(iodoacetamido)-fluorescein, methoxypolyethylene glycol 750 Da maleimide, 87 
methoxypolyethylene glycol 5000 Da maleimide, urea, chitosan (103 kDa), fluorescein 88 
isothiocyanate (FITC) and fluorescein isothiocyanate dextran (FITC-dextran) were 89 
purchased from Sigma-Aldrich (Gillingham, U.K.). Methanol was purchased from Fisher 90 
Scientific Ltd (UK) and used as received.  91 
 92 
2.2 SYNTHESIS OF THIOLATED SILICA NANOPARTICLES 93 
     Thiolated nanoparticles were synthesized according to our previously published 94 
protocol (Mun, 2014b). Briefly, 0.75 mL (0.2 mol/L) or 0.38 mL (0.1 mol/L) of MPTS was 95 
mixed with 20 mL of DMSO and 0.5 mL of 0.5 mol/L NaOH aqueous solution. 96 
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Additionally, the same procedure was repeated with 0.38 mL of MPTS in 20 mL of 97 
dimethylformamide (DMF) and acetonitrile.  The reaction was conducted with air 98 
bubbling and allowed to proceed for 24 hours under constant stirring at room 99 
temperature. Nanoparticles were purified by dialysis against deionized water (5L, 8 100 
changes of water) using 12‒14 kDa molecular weight cut off dialysis tubing (Medicell 101 
International Ltd, UK). 102 
 103 
2.3 ELLMAN’S ASSAY 104 
     Thiol-group content of the nanoparticles was determined by Ellman’s assay. 0.2-0.3 105 
mg of freeze-dried nanoparticles were hydrated in 500 µL of phosphate buffer solution 106 
(0.5mol/L, pH 8) and allowed to react with 500 µL of 5,5’-dithio-bis-(2-nitrobenzoic acid) 107 
(DTNB) for 2 hours. Absorbance was then measured at 420 nm (Epoch Microplate 108 
Spectrophotometer, BioTek Instruments, USA). The calibration curve was constructed 109 
with cysteine hydrochloride solutions over the concentration range of 25‒175 µmol/L (R2 110 
= 0.9998).  111 
 112 
2.4 SYNTHESIS OF FLUORESCENTLY-LABELLED THIOLATED SILICA 113 
NANOPARTICLES  114 
     Thiolated silica nanoparticles were labelled with 5-(iodoacetamido)-fluorescein (5-115 
IAF) by adding 3, 0.3, 0.4 and 0.05 mg of 5-IAF to 18, 20, 10 and 10 mL aqueous 116 
dispersions of thiolated nanoparticles, respectively. The amount of 5-IAF added was 117 
calculated with regard to molar ratios such that 5 µmol of fluorophore was added to 50 118 
µmol of SH-groups of thiolated nanoparticles. The reaction mixture was stirred for 16 119 
hours at room temperature protected from light. Fluorescently-labelled nanoparticles 120 
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were then purified by dialysis against deionized water in the dark, according to the 121 
above protocol. 122 
2.5 PEGYLATION OF FLUORESCENTLY-LABELLED SILICA NANOPARTICLES 123 
     5 mL aqueous dispersions of fluorescently-labelled nanoparticles were mixed with 124 
100 mg of methoxypolyethylene glycol maleimide of two molecular weights (750 or 5000 125 
Da). The reaction mixture was stirred during 16 hours at room temperature protected 126 
from light, resulting in the formation of PEGylated silica nanoparticles. PEGylated 127 
nanoparticles were purified by dialysis in the dark as above. 128 
 129 
2.6 SYNTHESIS OF FLUORESCENTLY-LABELLED CHITOSAN 130 
FITC-chitosan, used as a positive control for mucoadhesion tests, was 131 
synthesized according to our previously published protocol (Cook, 2011). 1% w/v 132 
chitosan solution was prepared in 100 mL of 0.1 mol/L acetic acid, followed by the 133 
addition of 100 mL of dehydrated methanol and 50 mL of 2 mg/mL FITC solution in 134 
methanol. The reaction was allowed to proceed for 3 hours in the dark at room 135 
temperature and then precipitated in 1 L of 0.1 M NaOH. The precipitate was filtered 136 
and dialyzed against 4 L of deionized water in the dark. The resulting product was 137 
freeze-dried (Heto Power Dry LL 3000 freeze-drier, Thermo Electron Corporation) and 138 
kept wrapped in aluminum foil to avoid exposure to light. For experiments, 0.05% 139 
solutions of FITC-chitosan in 0.1 M acetic acid were used.     140 
2.7 PREPARATION OF FLUORESCEIN ISOTHIOCYANATE DEXTRAN (4000 Da) 141 
(FITC-DEXTRAN) SOLUTION 142 
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     FITC-dextran solution, used as a negative control in mucoadhesion studies, was 143 
prepared by dissolving 2 mg of FITC-dextran (4000 Da) in 10 mL of deionized water and 144 
was left for 5 hours under permanent stirring at room temperature. 145 
2.8 DYNAMIC LIGHT SCATTERING (DLS) 146 
     The size of fluorescently-labelled silica nanoparticles and their polydispersity (PDI) 147 
values were determined by dynamic light scattering using a Nano-ZS series (Malvern 148 
Instruments, UK) at 25°C. Each sample was analyzed three times from which the mean 149 
± standard deviation hydrodynamic diameter values were calculated. 150 
 151 
 152 
2.9 FLUORESCENCE SPECTROSCOPY 153 
     Fluorescence spectra were recorded for fluorescently-labelled thiolated and 154 
PEGylated nanoparticles using a FP-6200 Spectrofluorometer (Jasco, UK) over the 155 
wavelength range 505‒700 nm (λex= 492 nm). 156 
 157 
2.10 PREPARATION OF ARTIFICIAL URINE SOLUTION  158 
     Artificial urine was prepared according to previously published protocol with slight 159 
modifications (Chutipongtanate and Thongboonkerd, 2010). The following compounds 160 
were dissolved in deionized water by stirring for 3 hours at room temperature, before 161 
making the total volume to 2 L: urea (24.27 g), NaCl (6.34 g), KCl (4.50 g), NH4Cl (1.61 162 
g), CaCl2 (0.67 g), MgSO4•7H2O (1.00 g), NaHCO3 (0.34 g), Na2SO4 (0.26 g), 163 
NaH2PO4•H2O (1.00 g), and Na2HPO4 (0.11 g). The pH of the resulting solution was 6.2, 164 
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which is in agreement with Chutipongtanate and Thongboonkerd (2010).  The artificial 165 
urine solution was kept at 37° C throughout the experiments. 166 
2.11 MUCOADHESION STUDIES USING PORCINE URINARY BLADDER 167 
     Mucoadhesive studies used a fluorescence microscope (Zeiss Imager A1) with an 168 
AxioCam MRm Zeiss camera at 5 × magnification with 11.4 ms exposure time and 1388 169 
× 1040 pixels. The porcine urinary bladders used in these experiments were obtained 170 
from P.C. Turner Abattoir (Hampshire, UK). Freshly-extracted urinary bladders were 171 
transported to the laboratory in a cold box and stored in the fridge at 4°C overnight prior 172 
to retention studies. A sample of the bladder tissue (approximately 2 × 3 cm) was 173 
carefully excised, avoiding contact with the mucosal side of the tissue, and was briefly 174 
rinsed with ~3 mL of artificial urine solution. Experiments were performed with the 175 
bladder tissue maintained at 37°C in a water bath. Background microscopy images 176 
were recorded for each tissue sample prior to dosing with 200 µL of either fluorescently-177 
labelled nanoparticle dispersion or polymers (controls). Once the test material was 178 
placed onto the mucosal surface, fluorescence microscopy images were again taken, 179 
followed by 7 washing cycles, for each of which the bladder tissue was irrigated with 10 180 
mL of artificial urine solution at 5 mL/min using a syringe pump. Fluorescence 181 
microscopy images (3 for each sample) were recorded initially after treatment and after 182 
each wash with the bladder tissue being placed onto a 75 mm x 25 mm glass slide. 183 
Each experiment was conducted in triplicate. Microscopy images were analysed with 184 
Image J software, the mean fluorescence values (fluorescence, a.u.) after each wash 185 
were calculated and a histogram of fluorescence intensity distribution was presented as 186 
a function of the volume of artificial urine solution used. The mean fluorescence values 187 
were normalized by subtracting the background fluorescence provided by the bladder 188 
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tissue prior to exposing it to the test material and the initial (pre-wash) fluorescence was 189 
taken as an intensity of 1.   190 
 Since the wash off experiments were not carried out in total darkness, to exclude the 191 
possibility of the fluorophore bleaching with time, a portion of thiolated nanoparticles 192 
dispersion was placed on the urinary bladder surface and fluorescence measured over 193 
5 hours. Figure S1 shows that no significant decrease (Anova, Tukey’s multiple 194 
comparison’s test, p=0.2247) in the fluorescence intensity of nanoparticle dispersion on 195 
the bladder surface was observed over 5 hours, indicating their suitability for this type of 196 
analysis.   197 
WO50 values, representing the volume of artificial urine required to wash out 50% of the 198 
particles, were calculated from the wash-off profiles. For example, WO50 values for 199 
chitosan and dextran were calculated via extrapolation of the wash-off results to 50 % 200 
using linear and exponential fits, respectively.  201 
 202 
 203 
3 RESULTS AND DISCUSSION 204 
3.1 SYNTHESIS AND CHARACTERIZATION OF FLUORESCENTLY-LABELLED 205 
THIOLATED AND PEGYLATED SILICA NANOPARTICLES 206 
Thiolated silica nanoparticles were synthesized using self-condensation of (3-207 
mercaptopropyl)trimethoxysilane (MPTS) in aprotic solvents in an oxidative environment 208 
(bubbling with air) and with small portions of aqueous NaOH as a catalyst. Previously 209 
(Mun, 2014b) we showed that the self-condensation of MPTS in dimethylsulfoxide forms 210 
nanoparticles of 21±1 nm and 45±1 nm, when the concentration of MPTS in the feed 211 
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mixture was 0.1mol/L and 0.2 mol/L, respectively. These two types of nanoparticles 212 
were also synthesized in the present study. Additionally, in this study we conducted the 213 
reaction in other aprotic solvents, namely dimethylformamide (DMF) and acetonitrile 214 
(AcN) for nanoparticle synthesis. Maintaining the MPTS at 0.1 mol/L, nanoparticles of 215 
95±14 and 217±7 nm were produced in DMF and AcN, respectively. The effect of 216 
aprotic solvent nature on the dimensions and properties of thiolated silica nanoparticles 217 
has not been reported previously. By changing the concentration of MPTS in the feed 218 
mixture and by changing the nature of aprotic solvent it is possible to make the thiolated 219 
silica nanoparticles with a range of different sizes. It is widely recognized (Plumere et al, 220 
2012) that formation of silica particles from alkoxysilanes (e.g. tetraalkoxysilane) 221 
proceeds via several stages such as hydroxysis, condensation, nucleation, aggregation 222 
and particle growth. The growth of primary particles as well as their further aggregation 223 
are dependent on thermodynamic parameters of the system controlling their colloidal 224 
stability. Polarity of the solvent is one of the factors affecting the particles at the 225 
nucleation stage. Smaller particles are expected to form in solvents of greater polarity 226 
(Wang et al, 2006), which was observed in this work.  227 
All nanoparticles were fluorescently labelled by reacting with 5-(iodoacetamido)-228 
fluorescein (5-IAF). The fluorophore was added into the reaction mixture in a 5:50 µmol 229 
ratio with regards to the number of SH-groups of silica nanoparticles; thus there were 230 
still numerous thiol-groups available for mucoadhesion and for further functionalization. 231 
The fluorescently labelled nanoparticles were characterized using dynamic light 232 
scattering, fluorescent spectroscopy and Ellman’s assay. Figure 1 shows size 233 
distributions of the nanoparticles formed in DMSO, DMF and AcN, determined using 234 
dynamic light scattering, illustrating the influence of changing solvent polarity on particle 235 
size, but with similar dispersities.   236 
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Previously (Irmukhametova et al, 2011) it was demonstrated that PEGylation prevents 237 
the adhesion of thiolated silica to intact bovine cornea, but could facilitate their 238 
penetration into more porous stroma in de-epithelialized cornea (Mun et al, 2014). 239 
Clearly, deeper penetration of particles into a biological tissue could also improve their 240 
retention, which means that PEGylation may have various effects on particle behavior 241 
on different mucosal surfaces. In this work the effect of thiolated silica PEGylation was 242 
studied in relation of urinary bladder mucosa.  243 
A portion of fluorescently-labelled thiolated nanoparticles synthesized in DMSO (45±1 244 
nm) was additionally reacted with PEG maleimide of two different molecular weights 245 
(750 Da and 5000 Da) to generate two PEGylated silica nanoparticles. The general 246 
characteristics of all silica nanoparticles synthesized in this work are summarized in 247 
Table 1. 248 
 249 
As expected, PEGylation generated larger nanoparticle size distributions, similar to our 250 
previous findings (Mun, 2014b). The sizes of thiolated and PEGylated nanoparticles 251 
were significantly different (ANOVA; Tukey’s multiple comparisons test; p<0.001) 252 
showing that the greater the molecular weight of PEG shell, the larger the nanoparticles. 253 
PEGylation also reduced thiol groups content from 249±30 µmol/g to 95±6 µmol/g and 254 
78±5 µmol/g, when the nanoparticles were decorated with 750 Da and 5000 Da PEG, 255 
respectively. Additionally, due to the screening effect of the PEG shells, reduced 256 
fluorescence intensity was observed for PEGylated nanoparticles. PEG of a larger 257 
molecular weight provided the lowest fluorescence intensity, since screening with PEG 258 
5000 Da is greater than with PEG 750 Da. For thiolated samples prepared in different 259 
solvents, the lowest fluorescence intensity was observed for those synthesized in 260 
12 
 
acetonitrile, which contained the lowest amount of SH-groups on their surface and 261 
hence a lower quantity of the fluorophore conjugated.  262 
 263 
 264 
3.2 COMPARATIVE MUCOADHESION STUDIES OF THIOLATED AND PEGYLATED 265 
NANOPARTICLES 266 
Bernkop-Schnurch introduced thiolated polymers (thiomers) as a new generation of 267 
mucoadhesive materials (Bernkop-Schnurch, 2005). Thiomers exhibit enhanced 268 
mucoadhesion compared to their unmodified parent polymers due to the formation of 269 
disulfide bridges (covalent bonds) between thiol-groups of the polymer and cysteine-rich 270 
domains of mucus glycoproteins. Barthelmes et al. (2011) reported the synthesis of 271 
chitosan-thioglycolic acid nanoparticles, loaded with trimethoprim, for targeted drug 272 
release in the urinary bladder. These nanoparticles enabled controlled and sustainable 273 
drug release, showed greater stability and superior mucoadhesion compared to 274 
unmodified chitosan particles. The presence of thiol groups on the surface of silica 275 
nanoparticles also makes them promising as mucoadhesive materials for application in 276 
drug delivery.   277 
The retention of fluorescently-labelled thiolated and PEGylated silica nanoparticles on 278 
porcine urinary bladder mucosa was studied using a flow-through method with 279 
fluorescent detection (Irmukhametova, 2011; Storha, 2013; Withers, 2013). Figure 2 280 
shows representative fluorescent images of the retention of thiolated and PEGylated 281 
silica as well as two controls (chitosan and dextran) on urinary bladder mucosa, washed 282 
with artificial urine. Fluorescently-labelled chitosan was selected as a positive control 283 
because it is a cationic polymer with well-documented ability to adhere to mucosal 284 
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surfaces (Sogias et al., 2008, Khutoryanskiy, 2011). Fluorescently-labelled dextran, on 285 
the contrary, had very poor adhesion to mucosal surfaces (Storha, 2013; Withers, 286 
2013), and so was used as a negative control in our experiments.  287 
Analysis of the fluorescent images using ImageJ software allows the retention of 288 
fluorescent species on mucosal surfaces to be quantified (Figure 3). FITC-chitosan is 289 
retained on the bladder surface even after 7 washes (total volume 70 mL) with artificial 290 
urine solution and illustrates its strong interaction with the mucosal surface. However, 291 
for FITC-dextran, a significant decrease in fluorescence was observed after the first 292 
wash (10 mL) with urine solution, confirming its poor mucoadhesive properties.  293 
 294 
 295 
Retention of thiolated silica nanoparticles on the bladder mucosa was significantly 296 
higher than for FITC-dextran (p<0.05): approximately 15% of the fluorescence, hence 297 
particles, remains on the mucosal surface even after 7 washing cycles with 10 mL of 298 
artificial urine solution. However, their retention was significantly lower than FITC-299 
chitosan (p<0.05). This may be due to the polymeric nature of chitosan, whose 300 
positively-charged macromolecules are able to penetrate into the mucosal layer of the 301 
bladder epithelium, form non-covalent interactions (e.g. electrostatic attraction and 302 
hydrogen bonding) with mucins and generate an interpenetration layer (Sogias, 2008). 303 
This interpenetration could potentially facilitate better retention of chitosan on the 304 
bladder mucosa compared to thiolated nanoparticles.  305 
PEGylated silica nanoparticles were washed from the mucosal surface more rapidly 306 
than the thiolated parent particles and hence are less mucoadhesive. The normalized 307 
fluorescence intensity of PEGylated (750 Da) nanoparticles on the bladder surface was 308 
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similar (T-test, p=0.8937) to that of its thiolated counterpart after the first wash. Whilst 309 
the thiolated nanoparticles stayed on the bladder surface after 7 washes, PEGylated 310 
(750 Da) nanoparticles were completely removed after 6 washes. PEGylated (5000 Da) 311 
nanoparticles revealed poorer retention than when modified with 750 Da PEG and were 312 
removed after 5 washes, similar to the negative control, FITC-dextran. Weaker retention 313 
for the PEGylated (5000 Da) silica relates to greater screening of the surface thiol 314 
groups by the larger molecular weight polymer and to the thiol content on the 315 
nanoparticle surface itself (Table 1).  316 
The poorer mucoadhesive performance of PEGylated nanoparticles compared to the 317 
thiolated silica is in good agreement with our previous study of retention of similar 318 
nanoparticles on the ocular surfaces (Irmukhametova, 2011). However, both thiolated 319 
and PEGylated (5000 Da) nanoparticles in our previous report demonstrated a very 320 
sharp drop in fluorescence intensity (of 62% and 95%, respectively) after the first wash 321 
and the  PEGylated nanoparticles were removed from the ocular surface after three 322 
washes. Here, PEGylated (PEG 5000 Da) nanoparticles were removed from the bladder 323 
mucosa after 6 wash cycles. This discrepancy can be explained by the different nature 324 
of two mucosal tissues (Irmukhametova et al., 2011); the rougher structure of the 325 
bladder epithelium compared to the cornea provides better retention of silica 326 
nanoparticles on its mucosal surface.  327 
Retention studies were conducted with differing sizes of thiolated silica nanoparticles, 328 
synthesized in different aprotic solvents (DMSO, DMF and AcN, Table 1). Figure 4 329 
shows the retention profiles for these nanoparticles.   330 
 331 
15 
 
The greatest retention in this series is observed for 21±1 nm thiolated nanoparticles, 332 
synthesized in DMSO: they remain on the surface of the bladder mucosa for up to 6-7 333 
washes with 10 mL of artificial urine. The nanoparticles synthesized in DMF are much 334 
larger (95±14 nm), but have similar thiol content as the thiolated silica prepared in 335 
DMSO (119±12 µmol/g and 118±14 µmol/g, respectively). Their retention on the bladder 336 
mucosa is poorer and no traces of these nanoparticles are detectable after 7 wash 337 
cycles. This clearly indicates that the nanoparticles of larger size have weaker retention 338 
on the bladder mucosa, which is possibly related to their poorer ability to penetrate into 339 
the mucosal layer. The weakest retention on the bladder mucosa was observed for the 340 
thiolated silica, synthesized in AcN. Both their large size (217±7 nm) and low SH-groups 341 
content (40±6 µmol/g) could contribute to this poor mucoadhesive performance.  342 
A comparison between the nanoparticles synthesized in DMSO from the feed mixtures 343 
containing different quantities of MPTS reveals that the thiolated silica of 45±1 nm 344 
(Figure 3) retains on the bladder mucosa better than 21±1 nm nanoparticles (Figure 4). 345 
This is explained by the greater thiol content (249±30 µmol/g) of the 45±1 nm particles 346 
compared to 21±1 nm material which had a lower concentration of SH-groups (118±14 347 
µmol/g).  348 
Direct quantitative comparisons between different wash-off profiles is problematic 349 
unless each set of data could be converted into a simple numerical value. To this end, 350 
we propose WO50 values, which represent the volume of a biological fluid required to 351 
wash out 50% of the mucoadhesive ingredient from a substrate surface. These values 352 
were calculated by analyzing individual wash-off profiles and the results are 353 
summarized in Table 1. By comparing these values for different particles used in this 354 
study, it is clear that the greatest retention is observed for 45±1 nm thiolated silica 355 
particles with the highest SH-groups content (249±30 mol/g), whose WO50 is 36 mL. 356 
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PEGylation of these particles reduces their retention with WO50 values dropping to 29 357 
and 8 mL for 750 Da and 5000 Da PEG, respectively. Thiolated nanoparticles have 358 
greater retention on bladder mucosa compared to non-mucoadhesive dextran (WO50 7 359 
mL), but have weaker mucoadhesive properties than chitosan (WO50 89 mL).    360 
The smallest thiolated particles of 21±1 nm diameter have a lower SH-groups content 361 
(118±14 mol/g) than those of 45±1 nm diameter and showed an expectedly lower 362 
WO50 of 17 mL. However, the nanoparticles synthesized in DMF are larger (95±14 nm), 363 
have  a similar SH-groups content (119±12 mol/g) but are more readily washed from 364 
the tissue (WO50 7mL). Hence the retention of particles on mucosal surfaces is not only 365 
dependent on their surface thiol-groups but also on their size. Indeed, the largest 366 
thiolated particles synthesized in acetonitrile (217±7 nm) have the lowest SH-groups 367 
content (40±6 mol/g) and exhibit weakest retention on mucosal surfaces (WO50 = 6 368 
mL).  369 
 370 
4.4 CONCLUSIONS 371 
     The retention of thiolated and PEGylated silica nanoparticles on porcine urinary 372 
bladder mucosa has been studied in vitro using fluorescence microscopy. It was shown 373 
that the thiolated nanoparticles adhere well to bladder mucosa and withstand wash out 374 
effects caused by urine. Retention of these nanoparticles depends on their thiol-content 375 
and dimensions. PEGylation of thiolated silica greatly reduces their mucoadhesive 376 
properties. The use of WO50 values, introduced in this work, provides a convenient 377 
method to quantitatively compare the retention of particulates and other materials on 378 
differing mucosal surfaces and between differing research protocols.  379 
 380 
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Captions to figures 496 
Figure 1. Size distribution of thiolated silica nanoparticles, fluorescently-labelled with 5-497 
IAF 498 
Figure 2. Exemplar fluorescence microphotographs showing retention of FITC-chitosan, 499 
thiolated silica, PEGylated silica (750 Da), PEGylated silica (5000 Da) and FITC-dextran 500 
on porcine urinary bladder mucosa as washed with different volumes of artificial urine 501 
solution. Scale bar is 200 µm. 502 
Figure 3. Fluorescence intensities showing retention of FITC-chitosan, thiolated silica, 503 
PEGylated silica (750 Da), PEGylated silica (5000 Da) and FITC-dextran on porcine 504 
urinary bladder mucosa after washing with different volumes of artificial urine solution. 505 
Each experiment was performed in triplicate and results are presented as the mean 506 
value ± standard deviation. Initial intensity after dosing is taken as a value of 1.  507 
Figure 4. Fluorescence levels showing retention of thiolated silica nanoparticles 508 
synthesized in DMSO, DMF and AcN on the urinary bladder surface washed with 509 
artificial urine. Each experiment was performed in triplicate and the results are 510 
presented as the mean value ± standard deviation.  511 
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 513 
Table 1. Characteristics of fluorescently-labelled thiolated and PEGylated silica 514 
nanoparticles  515 
Sample  Diameter, 
nm 
PDI Nanoparticle 
concentration, 
mg/mL 
[SH], 
µmol/g 
WO50 *, 
mL 
 
Thiolated (DMSO + 0.2 mol/L MPTS) 45±1 0.332 5 249±30 36  
PEGylated (750 Da) 54±1 0.194 5 95±6 29  
PEGylated (5000 Da) 69±2 0.145 7 78±5 8  
Thiolated (DMSO + 0.1 mol/L MPTS) 21±1 0.263 4 118±14 17  
Thiolated (DMF + 0.1 mol/L MPTS) 95±14 0.310 4 119±12 7  
Thiolated (AcN+ 0.1 mol/L MPTS) 217±7 0.056 3 40±6 6  
* WO50 is the volume of artificial urine required to wash out 50% of the particles 516 
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